BioSpecifics deal

BioSpecifics made a one-time cash payment to reduce the royalties it would owe to an undisclosed third-party for Xiaflex (formerly AA4500) to treat Peyronie's disease. The amount of the cash payment and the royalty rate are undisclosed. BioSpecifics also disclosed that it would owe a 0.5% royalty on net sales of the injectable form of collagenase ABC enzyme to treat Dupuytren's disease. ...